Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Curr Opin Cardiol. 2022 May 1;37(3):193–200. doi: 10.1097/HCO.0000000000000956

Figure 4.

Figure 4.

Effects of autologous c-kit-positive cardiac cells (CPCs), bone marrow mesenchymal stromal cells (MSCs), and their combination on cumulative incidence of HF-MACE in the CONCERT-HF trial: shown are results of intention-to-treat analysis. Reproduced with permission from [12].